Over the past decade, the development of ICI therapies with blocking antibodies directed against anti-CTLA-4, anti-PD-1, and anti-PD-L1 has totally changed the fate of metastatic melanoma patients thanks to their impressive therapeutic efficacy. The gene discussed is CTLA4; the disease is metastatic melanoma.